Unexpected Adverse Reactions and Safety Issues
First written in FY2016. 18 of 20 entries say "Restated". Latest entry: FY2023.
The whole theme swung hardest in 2026: 6 of 20 companies on the "Worse" side.
9 other companies' latest entry also says "Mitigated".
- FY2023MitigatedAnnual report
「The Group works to collect information on adverse effects and report it to regulatory authorities as necessary, regularly considers appropriate measures, and promotes the proper use of its products, including by revising precautions for use. For the raw materials it uses, the Group seeks to minimize risk by conducting acceptance testing, carrying out regular inspections of raw-material plants, and purchasing raw materials from multiple suppliers.」
Specific measures addressing adverse-effect and safety risks include collecting information on adverse effects, reporting to regulatory authorities, revising precautions, testing raw materials, inspecting plants, and purchasing from multiple suppliers. - FY2023-Q3RestatedAnnual report
「During the nine months ended the third quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It is stated that there were no new occurrences or material changes in the principal risks, including adverse effects and safety issues. - FY2023-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It is stated that there were no new occurrences or material changes in the principal risks, including adverse effects and safety issues. - FY2023-Q1RestatedAnnual report
「During the three months ended the first quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It is stated that there were no new occurrences or material changes in the principal risks, including adverse effects and safety issues. - FY2022-Q3RestatedAnnual report
「During the nine months ended the third quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It is stated that there were no new occurrences or material changes in the principal risks, including unexpected adverse effects and safety issues. - FY2022-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It is stated that there were no new occurrences or material changes in the principal risks, including unexpected adverse effects and safety issues. - FY2022-Q1RestatedAnnual report
「During the three months ended the first quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It is stated that there were no new occurrences or material changes in the principal risks, including unexpected adverse effects and safety issues. - FY2020RestatedAnnual report
「Unexpected adverse effects or safety concerns may arise in marketed pharmaceuticals and other products. If these adverse effects or safety concerns are serious, use of the pharmaceutical or other product may be restricted, or sales may be discontinued.」
The risk that pharmaceutical adverse effects or safety issues could lead to sales restrictions or discontinuation continues to be described. - FY2020-Q3RestatedAnnual report
「During the nine months ended the third quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It is stated that there were no new occurrences or material changes in the principal risks, including unexpected adverse effects and safety issues. - FY2020-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It is stated that there were no new occurrences or material changes in the principal risks, including unexpected adverse effects and safety issues. - FY2019RestatedAnnual report
「Unexpected adverse effects may be identified in marketed pharmaceuticals and other products. If these adverse effects are serious, use of the pharmaceutical or other product may be restricted, or sales may be discontinued.」
The risks related to pharmaceutical adverse effects and safety continue to be described. - FY2019-Q3RestatedAnnual report
「During the nine months ended the third quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It is stated that there were no new occurrences or material changes in the principal risks, including unexpected adverse effects and safety issues. - FY2019-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It is stated that there were no new occurrences or material changes in the principal risks, including unexpected adverse effects and safety issues. - FY2019-Q1RestatedAnnual report
「During the three months ended the first quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It is stated that there were no new occurrences or material changes in the principal risks, including unexpected adverse effects and safety issues. - FY2018-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It is stated that there were no new occurrences or material changes in the principal risks, including unexpected adverse effects and safety issues. - FY2017RestatedAnnual report
「Unexpected adverse effects may be identified in marketed pharmaceuticals and other products. If these adverse effects are serious, use of the pharmaceutical or other product may be restricted, or sales may be discontinued.」
The risks related to pharmaceutical safety and adverse effects continue to be described as before. - FY2017-Q3RestatedAnnual report
「During the nine months ended the third quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It is stated that there were no new occurrences or material changes in the principal risks, including unexpected adverse effects and safety issues. - FY2017-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It is stated that there were no new occurrences or material changes in the principal risks, including unexpected adverse effects and safety issues. - FY2017-Q1RestatedAnnual report
「During the three months ended the first quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It is stated that there were no new occurrences or material changes in the principal risks. - FY2016First statedAnnual report
「Unexpected adverse effects may be identified in marketed pharmaceuticals and other products. If these adverse effects are serious, use of the pharmaceutical or other product may be restricted, or sales may be discontinued.」
The potential impact on business results and financial condition if this occurs in a core product is described as a risk.